ReviewOncotarget2012
Advances in targeting signal transduction pathways.
Review in Oncotarget, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Phenylethanoid Glycoside-Enriched Extract Prepared fromAntioxidants (Basel, Switzerland) · 2023Article
- A multiscale cell-based model of tumor growth for chemotherapy assessment and tumor-targeted therapy through a 3D computational approach.Cell proliferation · 2022Article
- In vitro anti-cancer effect of marmesin by suppression of PI3K/Akt pathway in esophagus cancer cells.Esophagus : official journal of the Japan Esophageal Society · 2022Article
- Multiscale modeling of tumor growth and angiogenesis: Evaluation of tumor-targeted therapy.PLoS computational biology · 2021Article
- Measuring signal transduction and transcription molecules for clinical use.Asian biomedicine : research, reviews and news · 2020Article
- Tracking leukemic T-cell transcriptional dynamics in vivo with a blood-based reporter assay.FEBS open bio · 2020Article
- PKCβ1 regulates meiotic cell cycle in mouse oocyte.Cell cycle (Georgetown, Tex.) · 2019Article
- Verbascoside: Identification, Quantification, and Potential Sensitization of Colorectal Cancer Cells to 5-FU by Targeting PI3K/AKT Pathway.Scientific reports · 2018Article
- CEP55 promotes the proliferation, migration and invasion of esophageal squamous cell carcinoma via the PI3K/Akt pathway.OncoTargets and therapy · 2018Article
- Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy.Oncotarget · 2017Article
- mTOR activation is increased in pilocytic astrocytomas from older adults compared with children.Surgical neurology international · 2017Article
- A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.Investigational new drugs · 2016Article
- Six plant extracts delay yeast chronological aging through different signaling pathways.Oncotarget · 2016Article
- Article
- Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling.Oncotarget · 2016Article
- Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.Oncotarget · 2015Article
- Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.Oncotarget · 2015Article
- A systems-level interrogation identifies regulators of Drosophila blood cell number and survival.PLoS genetics · 2015Article
- A novel DAG-dependent mechanism links PKCɑ and Cyclin B1 regulating cell cycle progression.Oncotarget · 2014Article
- Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway.Oncotarget · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past few years, significant advances have occurred in both our understanding of the complexity of signal transduction pathways as well as the isolation of specific inhibitors which target key components in those pathways. Furthermore critical information is being accrued regarding how genetic mutations can affect the sensitivity of various types of patients to targeted therapy. Finally, genetic mechanisms responsible for the development of resistance after targeted therapy are being discovered which may allow the creation of alternative therapies to overcome resistance. This review will discuss some of the highlights over the past few years on the roles of key signaling pathways in various diseases, the targeting of signal transduction pathways and the genetic mechanisms governing sensitivity and resistance to targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.